AlloVir, Inc. (ALVR)
| Market Cap | 596.04M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -139.22M |
| Shares Out | 65.14M |
| EPS (ttm) | -2.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 309,475 |
| Open | 10.21 |
| Previous Close | 10.40 |
| Day's Range | 9.13 - 10.37 |
| 52-Week Range | 9.13 - 47.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 42.75 (+367.2%) |
| Earnings Date | Nov 9, 2021 |
About ALVR
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and hu...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for AlloVir stock is "Buy." The 12-month stock price forecast is 42.75, which is an increase of 367.21% from the latest price.
News
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir's Posoleucel for the Treatment of Ade...
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, a late-clinical stage allogeneic T-cell immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted its lead multi-virus...
AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present a...
AlloVir Announces Departure of Chief Medical Officer Augustin Melian
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR) today announced that Augustin Melian, MD, Chief Medical Officer, has decided to leave the company at the end of this year. Although officially lea...
AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 6...
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced preliminary data from the ongoing open-label portion of a Phase 2 ...
AlloVir to Host Virtual Investor Event
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced it will host a virtual investor event on Monday, December 13, 2021, at 8:00 a.m. EST....
AlloVir to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced today that the company will participate in the upcoming Piper Sandler 33rd Annual Vir...
AlloVir Reports Third Quarter 2021 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the third quarter ended September 30, 2021. The company also s...
FDA Grants Orphan Drug Designation (ODD) to AlloVir's Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Desi...
Data Presented at IDWeek™ 2021 Demonstrate that ALVR109, AlloVir's Investigational SARS-CoV-2-Specific T Cell Therapy...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced preclinical and early clinical data demonstrating that ALVR109, an investigat...
AlloVir to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate update at the Morgan Stanley 19th Annual Global Healthcare Conferenc...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fid...
New York, New York--(Newsfile Corp. - August 26, 2021) - Levi & Korsinsky announces it has commenced an investigation of Avalara, Inc. (NASDAQ: ALVR) concerning possible breaches of fiduciary duty. To o...
AlloVir Reports Second Quarter 2021 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the second quarter ended June 30, 2021....
AlloVir Reports First Quarter 2021 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the first quarter ended March 31, 2021....
AlloVir Appoints Diana M. Brainard, M.D.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced today that its Board of Directors has appointed Diana M. Brainard, M.D., as the company's...
AlloVir to Present at the 10th Annual SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 10th Annual SVB Leerink Globa...
AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced results of a subgroup analysis from a Phase 2, proof-of-conc...
AlloVir Reports Full Year 2020 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today provided a corporate update and reported full-year 2020 financial resu...
AlloVir Announces Data Presentations at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three oral presentations and one poster prese...
AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 39th Annual J.P. Morgan Healt...
AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-the-Shelf, Mu...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investi...
Company Profile for AlloVir
--(BUSINESS WIRE)--AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened imm...
Positive Phase 2 Proof-of-Concept Data for Viralym-M and Burden of Disease Data Presented in Oral Presentations at th...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that results from the Phase 2, proof-of-concept CHARMS study demon...
Preclinical Data Demonstrate Anti-Viral Activity of AlloVir's ALVR109, an Allogeneic, Off-the-Shelf SARS-CoV-2 Specif...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that preclinical data presented in an oral presentation at the 62n...
AlloVir to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the Piper Sandler 32nd Annual Virtual Healthcare Confere...
AlloVir Announces Oral Data Presentations at 62nd American Society of Hematology Annual Meeting
CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three abstracts as oral presentations that support ...